Subsetting the subsets: Heterogeneity and developmental relationships of T cells in human tumors

Cécile Alanio^{1

2

3

4

5}, E John Wherry^{6

2

3

7}

Affiliations

¹ Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
² Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
³ Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
⁴ INSERM U932, PSL University, Institut Curie, Paris 75005, France.
⁵ Laboratoire d'immunologie clinique, Institut Curie, Paris 75005, France.
⁶ Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu.
⁷ Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Comment

Cécile Alanio et al. Sci Immunol. 2021.

. 2021 Jul 23;6(61):eabj3067.

doi: 10.1126/sciimmunol.abj3067.

Cécile Alanio^{1

2

3

4

5}, E John Wherry^{6

2

3

7}

¹ Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
² Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
³ Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
⁴ INSERM U932, PSL University, Institut Curie, Paris 75005, France.
⁵ Laboratoire d'immunologie clinique, Institut Curie, Paris 75005, France.
⁶ Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu.
⁷ Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Abstract

High-dimensional profiling approaches inform developmental relationships between tumor-infiltrating lymphocyte subpopulations.

Contribution of resident and circulating precursors to tumor-infiltrating CD8⁺ T cell populations in lung cancer.
Gueguen P, Metoikidou C, Dupic T, Lawand M, Goudot C, Baulande S, Lameiras S, Lantz O, Girard N, Seguin-Givelet A, Lefevre M, Mora T, Walczak AM, Waterfall JJ, Amigorena S. Gueguen P, et al. Sci Immunol. 2021 Jan 29;6(55):eabd5778. doi: 10.1126/sciimmunol.abd5778. Sci Immunol. 2021. PMID: 33514641